Category Archives: Cancer Therapies

Mikhail Blagosklonny: Harnessing the Potential of Rapamycin

Mankind has been fascinated with being immortal for years. Lore and myth surrounding immortal beings are prevalent in ancient civilizations, and mankind has been researching how to attain eternal life. Recently, a group of scientists from the United States have proposed a theory on how immortality can be achieved. According to the theory, the key to immortality is understanding that aging is actually a disease that can be cured, and the substance to be used is rapamycin, which is currently being used against cancer and all of its effects. The leader of the group researching on rapamycin is Dr. Mikhail Blagosklonny, who is an oncologist and a professor at the Roswell Park Cancer Institute. Dr. Mikhail Blagosklonny have presented his research to the scientific community a few years ago, but they ridiculed him and told him that immortality is based on fantasy. The experience he had facing the scientific community inspired him to do further research, to prove the scientists who thought about his idea as a ridiculous fantasy wrong.

Dr. Mikhail Blagosklonny graduated from the First Pavlov State Medical University of St. Petersburg, and he received several degrees during his study. Right after graduation, he moved to the Roswell Park Cancer Institute to become a professor of oncology, and his fascination with immortality stemmed from his discovery about the potential use of rapamycin. Being a professor who is teaching about cancer, its causes, and the possible cure, he is exposed to different chemicals and substances which are being used today against the disease. One day, upon researching about cancer, he discovered that rapamycin can actually regenerate cells which have been degenerated. This curiosity managed to spawn several other studies, confirming his theory about the substance. He immediately formed a team of scientists who will be studying the substance and their goal is to find out how rapamycin can be made into a wonder drug.

Based on the research of Dr. Mikhail Blagosklonny, rapamycin has two centric models, called the TOR and the MTOR model. These centric models are responsible for the regeneration of the cells inside the body. They wanted to find out how rapamycin with TOR and MTOR model can be obtained, and through studying thoroughly, they found out that these centric models can be obtained from genes, which makes it passable to off springs; it can also be obtained through cellular senescence, which means that newer cells that has been regenerated can have the centric models; and finally, is from diseases. Their study also found out that rapamycin can actually strengthen one’s immune system, and the cells which have been deteriorated can return back to its juvenile state.The research of Dr. Mikhail Blagosklonny made headlines, and soon, other pharmaceutical companies have started their venture on discovering the key to immortality. They are basing their production on the research of Dr. Mikhail Blagosklonny, and one of these companies who are serious about being the first one to introduce the key to immortality is Novartis. Dr. Mikhail Blagosklonny must race against time to be given the proper credit.

All About Entrepreneur Eric Lefkofsky

Eric Lefkofsky is one of the most successful entrepreneurs in America today. As one of the co-founders of Groupon, he has made a big impact in a number of industries. Today, Lefkofsky is CEO of Tempus. This startup has the ambitious goal of curing cancer. It’s a challenge not many people would want to take on. But Eric Lefkofsky has never shied away from a challenge.

Lefkofsky is a graduate of the University of Michigan, and the University of Michigan Law School. This is an unusual background for someone at the helm of a healthcare and technology company. However, Lefkofsky believes he has identified some key weaknesses in today’s standard cancer treatments and more information click here.

The first issue is that every patient is unique. From DNA to environmental factors such as diet, each patient will have nuances differentiate their case from others. Likewise, every tumor is also unique. By identifying the building blocks of each tumor, and measuring its growth rate, highly targeted treatments could be developed and learn more about Eric.

The second issue is that providers are only human. Even with the best of intuition and intent, there is only so much a doctor can do. With better data, they can recommend better treatments. Tempus processes reams of data that normally be impossible for humans to get through. By digesting a large quantity of data, Tempus gives medical providers an analytical tool to do their job more effectively and Eric’s lacrosse camp.

With personalized information, Eric Lefkofsky and the rest of the Tempus team hope to revolutionize cancer treatment. By collecting and tracking individual tumors, the hope is that survival rates will increase. And eventually, trends will emerge that could lead to a cure for cancer and his Facebook.

Eric Lefkofsky’s newest venture truly has the potential to change the world. It marries his keen business mind with his drive to make the world a better place. In addition to his career as an entrepreneur, Lefkofsky is always finding ways to give back to his community. For example, he serves as a Trustee for Lurie Children’s Hospital of Chicago, Steppenwolf Theatre Company and other worthy non-profit organizations.

Oncotarget With Precision

Due to the uptick in technological advances, humankind remains lazier than ever. To expound further, humankind remains less reliant on themselves to get tasks done. As a result, they exercise less. Due to this lack of exercise, humankind finds themselves susceptible to numerous health problems. To name a few, these include obesity, diabetes, heart attacks, strokes, and cancer. With that being said, humankind’s anatomy remains unable to combat such ailments without exercising and eating healthy. Therefore, it remains pertinent for people to incorporate these vices into their regular daily regimen. With that being said, it would greatly reduce the risk of obtaining such ailments. In particular, cancer remains a condition that kills millions of people each year. This remains attributed to things such as smoking.

Although people cannot cure all forms of cancer, significant advancements have taken place. Moreover, companies such as Oncotarget have contributed significantly to finding cures for cancer. For those unaware, Oncotarget remains an industry leader. Moreover, Oncotarget remains a peer-reviewed online medical journal. Furthermore, the publication receives updates on a weekly basis. Also, the publication focuses its efforts on creating cures for cancer. In other words, the company focuses on all things pertaining to oncology. With that being said, the company began its operations in 2010 and remains published by Impact Journals. In addition, the publication includes two main editors. These include Mikhail Blagosklonny and Andrei V.

When it comes to reviewing articles, the process remains simple. It works by requiring authors to provide reputable references to other recent papers in the journal. In addition, the publication outlines its submission requirements. Prior to submitting a manuscript for publication, it remains pertinent for authors to read the instructions. When an author submits their manuscript to the publication, it implies that they accept the publication’s terms of an agreement. In addition, Mikhail Blagosklonny remains crucial to the success of the publication. As a scientist who has studied cancer for decades, Blagoskolonny remains in a position to manage the publication. In addition, he also served as a professor of oncology in New York at the Roswell Park Cancer Institute.

To know more click here



Clay Siegall: A Legend in Cancer Therapies

Clay Siegall founded Seattle Genetics in 1998. The Company is a Bio-Tech firm that deals with targeted therapies for diseases that have not seen any improvements in the past years.

Clay is the C.E.O of the Seattle Genetics and has led the Company to achieve great success. He led the company to develop its first antibody conjugate. This was the first FDA approved drug.

Seattle Genetics has also created 20 drugs with renowned drug manufacturers. Seattle Genetics has grown to become a force of nature in the Cancer industry. Siegall has positioned the Company to become a voice of authority in the 21st century.

Clay Siegall attended the University of Maryland where he graduated with a Bachelor of Science in Zoology. He later received a Ph.D. in Genetics from the University of Washington.

From a young age, Clay has been interested in Medicine and the technology to overcome diseases. In an interview, Clay said that he developed an interest in Cancer after he saw a family member go through a brutal experience with cancer.

While money was a great motivation for him pursuing launching his Company, Clay said he wanted to create an alternative therapy to alleviate the pain of cancer and chemotherapy.

The Company raises its money from the drugs that they have developed. Seattle also generates revenue from the partnerships and licenses of their technologies. According to Clay, the company became successful and profitable after ten years of in the industry. When the Company was launched, Clay managed to get $675 million through private and public finances.

Unlike most businesses, Seattle uses a unique marketing strategy to promote their services. The team spends a significant amount of time to negotiate contracts. They have also gained a great legal team.

Before launching the Company, Clay worked for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Prior to that Clay worked with the National Cancer Institute. Clay also served as a member of the Board of Director of the Alder BioPharmaceuticals.

Clay is an author and published over 70 publications. He also holds 15 patents.